Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of October 2015. The document reports on corporate governance actions taken during the Annual General Meeting of Shareholders held on October 29, 2015.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder resolutions and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document details the following corporate actions approved by shareholders:
- Appointment of Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) as the Company's auditors for the year 2015 and until the next Annual General Meeting.
- Authorization of the Board and Audit Committee to determine auditor fees.
- Re-election of Dr. Kenneth Reed and Mr. Eric Swenden to the Board of Directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the results of the shareholder meeting and incorporates by reference into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the independence and qualifications of the newly appointed auditors, Kesselman & Kesselman.
- Confirm the tenure and background of the re-elected board members, Dr. Kenneth Reed and Mr. Eric Swenden.
- Review the referenced Registration Statements (Form S-8 No. 333-188286 and Form F-3 No. 333-193503) for broader corporate context.